Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EFTR eFFECTOR Therapeutics Inc

-0.04 (-2.06%)
Last Updated: 11:59:48
Delayed by 15 minutes


Draw Mode:

Volume 73,414
Bid Price 1.90
Ask Price 1.91
News -
Day High 1.99


52 Week Range


Day Low 1.87
Company Name Stock Ticker Symbol Market Type
eFFECTOR Therapeutics Inc EFTR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -2.06% 1.90 11:59:48
Open Price Low Price High Price Close Price Prev Close
1.93 1.87 1.99 1.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
338 73,414 $ 1.89 $ 138,873 - 1.60 - 37.00
Last Trade Time Type Quantity Stock Price Currency
12:01:23 10 $ 1.90 USD

eFFECTOR Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.63M 3.00M - 0 -35.81M -11.95 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

eFFECTOR Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EFTR Message Board. Create One! See More Posts on EFTR Message Board See More Message Board Posts

Historical EFTR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.062.061.871.9994,334-0.16-7.77%
1 Month1.672.341.63122.02123,5210.2313.77%
3 Months11.0717.751.605.44402,586-9.17-82.84%
6 Months15.2517.901.6011.271,149,687-13.35-87.54%
1 Year18.2937.001.6016.491,261,373-16.39-89.61%
3 Years475.001,010.501.60117.11774,889-473.10-99.60%
5 Years475.001,010.501.60117.11774,889-473.10-99.60%

eFFECTOR Therapeutics Description

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

Your Recent History

Delayed Upgrade Clock